Ursofalk 250mg Capsules N100
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Ursodeoxycholic acid
Release form
Capsules
Composition
Active ingredient: Ursodeoxycholic acid (Ursodeoxycholic acid) Active substance concentration (mg): 250
Pharmacological effect
Hepatoprotector. It has a choleretic effect. Reduces the synthesis of cholesterol in the liver, its absorption in the intestines and concentration in bile, increases the solubility of cholesterol in the biliary system, stimulates the formation and excretion of bile. Reduces the lithogenicity of bile, increases the content of bile acids. It causes an increase in gastric and pancreatic secretion, enhances the activity of lipase. It has a hypoglycemic effect. It causes partial or complete dissolution of cholesterol stones when ingested, reduces the saturation of bile with cholesterol, which mobilizes cholesterol from gallstones. It has an immunomodulatory effect, affects the immune reactions in the liver: reduces the expression of certain antigens on the hepatocyte membrane, affects the number of T-lymphocytes, the formation of interleukin-2, reduces the number of honors eosinophils.
Pharmacokinetics
Data on the pharmacokinetics of the drug Ursofalk not provided.
Indications
Dissolving cholesterol gallstones; biliary reflux gastritis; primary biliary cirrhosis in the absence of signs of decompensation (symptomatic treatment); chronic hepatitis of various genesis; primary sclerosing cholangitis, cystic fibrosis (cystic fibrosis); non-alcoholic steatohepatitis; alcoholic liver disease; biliary dyskinesia.
Contraindications
X-positive (high calcium) gallstones; nonfunctioning gallbladder; acute inflammatory diseases of the gallbladder, bile ducts and intestines; cirrhosis of the liver in the stage of decompensation; severe renal impairment; severe liver dysfunction; pronounced dysfunction of the pancreas; pregnancy; lactation period (breastfeeding); hypersensitivity to the drug.
Precautionary measures
Ursofalk is administered under the supervision of a physician. During the first 3 months of treatment, indicators of liver function should be monitored: transaminase, alkaline phosphatase and GGT activity in the serum every 4 weeks, and then every 3 months. Monitoring these parameters allows you to identify abnormal liver function in the early stages.This also applies to patients in the later stages of primary biliary cirrhosis. In addition, it is possible to quickly determine whether a patient reacts with primary biliary cirrhosis to the treatment being given.
Use during pregnancy and lactation
The drug is contraindicated in pregnancy and lactation (breastfeeding).
Dosage and administration
The daily dose is set depending on the evidence. Capsules should be taken without chewing, in the evening, before going to bed, with a small amount of liquid. The drug should be taken regularly. The required duration of application can be 6-24 months. If, after 12 months of use of the drug, a reduction in the size of stones does not occur, further continuation of therapy is not appropriate. The effectiveness of therapy is monitored by ultrasound or radiographically every 6 months. With the development of calcification of stones, treatment is stopped.
Side effects
Mushy stools, diarrhea; pain in the right hypochondrium; calcification of calculus, skin rash, urticaria.
Overdose
No cases of overdose have been identified. In case of overdose, symptomatic treatment is carried out.
Interaction with other drugs
Kolestiramin, colestipol and antacids containing aluminum hydroxide or smectite (aluminum oxide) reduce the absorption of ursodeoxycholic acid in the intestine and thus reduce its absorption and effectiveness. If the use of drugs containing at least one of these substances is still necessary, they should be taken at least 2 hours before taking Ursofalk. Ursodeoxycholic acid can increase the absorption of cyclosporine from the intestine. Therefore, in patients receiving cyclosporine, the physician should check the concentration of cyclosporine in the blood and adjust the dose of cyclosporine if necessary. In some cases, Ursofalk can reduce the absorption of ciprofloxacin. ability to dissolve cholesterol gallstones.
special instructions
When used to dissolve cholesterol gallstones, in orderin order to assess progress in treatment and to timely detect signs of calcification of stones, depending on the size of the stones, the gallbladder should be visualized (oral cholecystography) with an examination of blackouts in the standing and supine position (ultrasound examination) 6-10 months after the start of treatment. the gallbladder cannot be visualized on X-rays or in cases of calcification of the stones, weak contractility of the gallbladder or frequent attacks of colic, the drug Ursofalk should not be used. When treating Patients in the late stages of primary biliary cirrhosis. Very rarely there have been cases of decompensation of liver cirrhosis. After discontinuation of therapy, partial reversal of manifestations of decompensation was noted. Patients with diarrhea should reduce the dose of the drug. With persistent diarrhea, treatment should be discontinued. Effects on the ability to drive vehicles and control mechanisms Effects on the ability to drive vehicles and moving mechanisms have been identified.